

# Lorenzo Trippa

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/104668/publications.pdf>

Version: 2024-02-01

76  
papers

3,486  
citations

172457

29  
h-index

155660

55  
g-index

77  
all docs

77  
docs citations

77  
times ranked

5390  
citing authors

#	ARTICLE	IF	CITATIONS
1	Inference in response-adaptive clinical trials when the enrolled population varies over time. <i>Biometrics</i> , 2023, 79, 381-393.	1.4	1
2	The use of external control data for predictions and futility interim analyses in clinical trials. <i>Neuro-Oncology</i> , 2022, 24, 247-256.	1.2	29
3	Integration of survival data from multiple studies. <i>Biometrics</i> , 2022, 78, 1365-1376.	1.4	3
4	A Bayesian Multi-Outcome Analysis of Fine Particulate Matter and Cardiorespiratory Hospitalizations. <i>Epidemiology</i> , 2022, 33, 176-184.	2.7	0
5	Cardiac outcomes of subjects on adjuvant trastuzumab emtansine vs paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT) study (TBCRC033): a randomized controlled trial. <i>Npj Breast Cancer</i> , 2022, 8, 18.	5.2	8
6	Optimality of testing procedures for survival data in the nonproportional hazards setting. <i>Biometrics</i> , 2021, 77, 587-598.	1.4	5
7	Oncotype DX testing in node-positive breast cancer strongly impacts chemotherapy use at a comprehensive cancer center. <i>Breast Cancer Research and Treatment</i> , 2021, 185, 215-227.	2.5	10
8	Rationale and design of the Novel Uses of adaptive Designs to Guide provider Engagement in Electronic Health Records (NUDGE-EHR) pragmatic adaptive randomized trial: a trial protocol. <i>Implementation Science</i> , 2021, 16, 9.	6.9	14
9	KMDATA: a curated database of reconstructed individual patient-level data from 153 oncology clinical trials. <i>Database: the Journal of Biological Databases and Curation</i> , 2021, 2021, .	3.0	1
10	The effects of releasing early results from ongoing clinical trials. <i>Nature Communications</i> , 2021, 12, 801.	12.8	4
11	Assessment of Simulated SARS-CoV-2 Infection and Mortality Risk Associated With Radiation Therapy Among Patients in 8 Randomized Clinical Trials. <i>JAMA Network Open</i> , 2021, 4, e213304.	5.9	4
12	Impact of HER2 Heterogeneity on Treatment Response of Early-Stage HER2-Positive Breast Cancer: Phase II Neoadjuvant Clinical Trial of T-DM1 Combined with Pertuzumab. <i>Cancer Discovery</i> , 2021, 11, 2474-2487.	9.4	92
13	Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial. <i>Journal of Clinical Oncology</i> , 2021, 39, 2375-2385.	1.6	76
14	Leveraging external data in the design and analysis of clinical trials in neuro-oncology. <i>Lancet Oncology</i> , The, 2021, 22, e456-e465.	10.7	53
15	A phase II study of cabozantinib alone or in combination with trastuzumab in breast cancer patients with brain metastases. <i>Breast Cancer Research and Treatment</i> , 2020, 179, 113-123.	2.5	26
16	Meta-Analysis of PD-L1 Expression As a Predictor of Survival After Checkpoint Blockade. <i>JCO Precision Oncology</i> , 2020, 4, 1196-1206.	3.0	9
17	A Phase II Study of Pembrolizumab in Combination With Palliative Radiotherapy for Hormone Receptor-positive Metastatic Breast Cancer. <i>Clinical Breast Cancer</i> , 2020, 20, 238-245.	2.4	44
18	Effect of Eribulin With or Without Pembrolizumab on Progression-Free Survival for Patients With Hormone Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer. <i>JAMA Oncology</i> , 2020, 6, 1598.	7.1	84

#	ARTICLE	IF	CITATIONS
19	Prediction of Outcomes with a Computational Biology Model in Newly Diagnosed Glioblastoma Patients Treated with Radiation Therapy and Temozolomide. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 716-724.	0.8	7
20	Shared and Usable Data From Phase 1 Oncology Trials—An Unmet Need. <i>JAMA Oncology</i> , 2020, 6, 980.	7.1	4
21	Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 2556-2564.	7.0	109
22	Estimating the Effects of Fine Particulate Matter on 432 Cardiovascular Diseases Using Multi-Outcome Regression With Tree-Structured Shrinkage. <i>Journal of the American Statistical Association</i> , 2020, 115, 1689-1699.	3.1	3
23	Pathologic Complete Response after Neoadjuvant Chemotherapy and Impact on Breast Cancer Recurrence and Survival: A Comprehensive Meta-analysis. <i>Clinical Cancer Research</i> , 2020, 26, 2838-2848.	7.0	403
24	A quantitative framework for modeling COVID-19 risk during adjuvant therapy using published randomized trials of glioblastoma in the elderly. <i>Neuro-Oncology</i> , 2020, 22, 918-927.	1.2	15
25	Avoiding Peg-Filgrastim Prophylaxis During the Paclitaxel Portion of the Dose-Dense Doxorubicin-Cyclophosphamide and Paclitaxel Regimen: A Prospective Study. <i>Journal of Clinical Oncology</i> , 2020, 38, 2390-2397.	1.6	9
26	Genomic Profiling of Smoldering Multiple Myeloma Identifies Patients at a High Risk of Disease Progression. <i>Journal of Clinical Oncology</i> , 2020, 38, 2380-2389.	1.6	110
27	Bayesian Uncertainty Directed Trial Designs. <i>Journal of the American Statistical Association</i> , 2019, 114, 962-974.	3.1	8
28	Phase I/II trial of the CXCR4 inhibitor plerixafor in combination with bortezomib as a chemosensitization strategy in relapsed/refractory multiple myeloma. <i>American Journal of Hematology</i> , 2019, 94, 1244-1253.	4.1	42
29	Ribociclib Plus Trastuzumab in Advanced HER2-Positive Breast Cancer: Results of a Phase 1b/2 Trial. <i>Clinical Breast Cancer</i> , 2019, 19, 399-404.	2.4	27
30	Design and Evaluation of an External Control Arm Using Prior Clinical Trials and Real-World Data. <i>Clinical Cancer Research</i> , 2019, 25, 4993-5001.	7.0	57
31	To randomize, or not to randomize, that is the question: using data from prior clinical trials to guide future designs. <i>Neuro-Oncology</i> , 2019, 21, 1239-1249.	1.2	16
32	Progression Risk Stratification of Asymptomatic Waldenström Macroglobulinemia. <i>Journal of Clinical Oncology</i> , 2019, 37, 1403-1411.	1.6	65
33	Lessons Learned from Deescalation Trials in Favorable Risk HPV-Associated Squamous Cell Head and Neck Cancer—A Perspective on Future Trial Designs. <i>Clinical Cancer Research</i> , 2019, 25, 7281-7286.	7.0	19
34	Deviation from the Proportional Hazards Assumption in Randomized Phase 3 Clinical Trials in Oncology: Prevalence, Associated Factors, and Implications. <i>Clinical Cancer Research</i> , 2019, 25, 6339-6345.	7.0	48
35	Multi-Study Factor Analysis. <i>Biometrics</i> , 2019, 75, 337-346.	1.4	33
36	A Phase II Study of Daratumumab in Patients with High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma: First Report of Efficacy and Safety. <i>Blood</i> , 2019, 134, 1898-1898.	1.4	6

#	ARTICLE	IF	CITATIONS
37	The clinical trials landscape for glioblastoma: is it adequate to develop new treatments?. <i>Neuro-Oncology</i> , 2018, 20, 1034-1043.	1.2	100
38	Adding experimental arms to platform clinical trials: randomization procedures and interim analyses. <i>Biostatistics</i> , 2018, 19, 199-215.	1.5	19
39	Hazards of Hazard Ratios "Deviations from Model Assumptions in Immunotherapy. <i>New England Journal of Medicine</i> , 2018, 378, 1158-1159.	27.0	79
40	Bayesian Adaptive Randomization in Dose-Finding Trials. <i>JAMA Network Open</i> , 2018, 1, e186075.	5.9	2
41	Bortezomib overcomes the negative impact of CXCR4 mutations on survival of Waldenström macroglobulinemia patients. <i>Blood</i> , 2018, 132, 2608-2612.	1.4	29
42	Efficient computation of the joint probability of multiple inherited risk alleles from pedigree data. <i>Genetic Epidemiology</i> , 2018, 42, 528-538.	1.3	3
43	A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-eligible multiple myeloma. <i>British Journal of Haematology</i> , 2018, 182, 222-230.	2.5	118
44	Unbiased estimation for response adaptive clinical trials. <i>Statistical Methods in Medical Research</i> , 2017, 26, 2376-2388.	1.5	29
45	Prognostic role of circulating exosomal miRNAs in multiple myeloma. <i>Blood</i> , 2017, 129, 2429-2436.	1.4	214
46	Bayesian Nonparametric Ordination for the Analysis of Microbial Communities. <i>Journal of the American Statistical Association</i> , 2017, 112, 1430-1442.	3.1	30
47	Feasibility of Ultra-High-Throughput Functional Screening of Melanoma Biopsies for Discovery of Novel Cancer Drug Combinations. <i>Clinical Cancer Research</i> , 2017, 23, 4680-4692.	7.0	8
48	Leveraging molecular datasets for biomarker-based clinical trial design in glioblastoma. <i>Neuro-Oncology</i> , 2017, 19, 908-917.	1.2	23
49	Bayesian Response-Adaptive Designs for Basket Trials. <i>Biometrics</i> , 2017, 73, 905-915.	1.4	38
50	Combining Bayesian experimental designs and frequentist data analyses: motivations and examples. <i>Applied Stochastic Models in Business and Industry</i> , 2017, 33, 302-313.	1.5	11
51	A Bayesian response-adaptive trial in tuberculosis: The <i>endTB</i> trial. <i>Clinical Trials</i> , 2017, 14, 17-28.	1.6	32
52	Designing Clinical Trials That Accept New Arms: An Example in Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 2017, 35, 3160-3168.	1.6	28
53	Bayesian Baskets: A Novel Design for Biomarker-Based Clinical Trials. <i>Journal of Clinical Oncology</i> , 2017, 35, 681-687.	1.6	30
54	Robust lineage reconstruction from high-dimensional single-cell data. <i>Nucleic Acids Research</i> , 2016, 44, e122-e122.	14.5	30

#	ARTICLE	IF	CITATIONS
55	On the Restricted Mean Survival Time Curve in Survival Analysis. <i>Biometrics</i> , 2016, 72, 215-221.	1.4	176
56	Mitigating Bias in Generalized Linear Mixed Models: The Case for Bayesian Nonparametrics. <i>Statistical Science</i> , 2016, 31, 80-95.	2.8	6
57	Optimal Bayesian Adaptive Trials When Treatment Efficacy Depends on Biomarkers. <i>Biometrics</i> , 2016, 72, 414-421.	1.4	6
58	Subgroup-Based Adaptive (SUBA) Designs for Multi-arm Biomarker Trials. <i>Statistics in Biosciences</i> , 2016, 8, 159-180.	1.2	33
59	Getting it first versus getting it right: weighing the value of and evidence for progression-free survival as a surrogate endpoint for overall survival in glioblastoma. <i>Neuro-Oncology</i> , 2015, 17, 765-766.	1.2	3
60	Combining progression-free survival and overall survival as a novel composite endpoint for glioblastoma trials. <i>Neuro-Oncology</i> , 2015, 17, 1106-1113.	1.2	21
61	Clinical implementation of integrated whole-genome copy number and mutation profiling for glioblastoma. <i>Neuro-Oncology</i> , 2015, 17, 1344-1355.	1.2	40
62	Bayesian Designs and the Control of Frequentist Characteristics: A Practical Solution. <i>Biometrics</i> , 2015, 71, 218-226.	1.4	30
63	Brain Malignancy Steering Committee clinical trials planning workshop: Report from the Targeted Therapies Working Group. <i>Neuro-Oncology</i> , 2015, 17, 180-188.	1.2	28
64	Progression-free survival: too much risk, not enough reward?. <i>Neuro-Oncology</i> , 2014, 16, 615-616.	1.2	16
65	A comparison of Bayesian adaptive randomization and multi-stage designs for multi-arm clinical trials. <i>Statistics in Medicine</i> , 2014, 33, 2206-2221.	1.6	98
66	Cross-study validation for the assessment of prediction algorithms. <i>Bioinformatics</i> , 2014, 30, i105-i112.	4.1	75
67	Bifurcation analysis of single-cell gene expression data reveals epigenetic landscape. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, E5643-50.	7.1	263
68	Risk Prediction for Late-Stage Ovarian Cancer by Meta-analysis of 1525 Patient Samples. <i>Journal of the National Cancer Institute</i> , 2014, 106, .	6.3	184
69	A Toolbox for Spatiotemporal Analysis of Voltage-Sensitive Dye Imaging Data in Brain Slices. <i>PLoS ONE</i> , 2014, 9, e108686.	2.5	14
70	Biomarker-based adaptive trials for patients with glioblastoma--lessons from I-SPY 2. <i>Neuro-Oncology</i> , 2013, 15, 972-978.	1.2	37
71	Defining Predictive Probability Functions for Species Sampling Models. <i>Statistical Science</i> , 2013, 28, 209-222.	2.8	34
72	Bayesian Adaptive Randomized Trial Design for Patients With Recurrent Glioblastoma. <i>Journal of Clinical Oncology</i> , 2012, 30, 3258-3263.	1.6	104

#	ARTICLE	IF	CITATIONS
73	Bayesian Enrichment Strategies for Randomized Discontinuation Trials. <i>Biometrics</i> , 2012, 68, 203-211.	1.4	14
74	A Class of Normalized Random Measures with an Exact Predictive Sampling Scheme. <i>Scandinavian Journal of Statistics</i> , 2012, 39, 444-460.	1.4	5
75	Extended Bernstein prior via reinforced urn processes. <i>Annals of the Institute of Statistical Mathematics</i> , 2011, 63, 481-496.	0.8	3
76	The multivariate beta process and an extension of the Polya tree model. <i>Biometrika</i> , 2011, 98, 17-34.	2.4	29